New vaccine candidate could be a cost-effective option against emerging SARS-CoV-2 variants
A multidisciplinary team of researchers is the first to show combining yeast-expression technology and a novel adjuvant formulation to produce a COVID-19 vaccine candidate is effective against SARS-COV-2 and promises to be easy to produce at large scale and cost-effective, important aspects for vaccinating people worldwide, especially in low- to middle-income countries. Results from the study, which applied lessons learned from the hepatitis b vaccine platform technology, are published online today in
Science Immunology.
Researchers from the Yerkes National Primate Research Center (NPRC) at Emory University, Infectious Disease Research Institute (IDRI), 3M and Texas Children s Hospital s Center for Vaccine Development at Baylor College of Medicine paired Baylor s SARS-CoV-2 Receptor Binding Domain (RBD) recombinant protein formulation vaccine candidate with IDRI s aluminum-based formulatio
New COVID-19 vaccine candidate provides effective option for low- to mid-income countries eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.